Revolution Medicines (RVMD) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free RVMD Stock Alerts $38.71 +0.54 (+1.41%) (As of 12:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 3:22 PM | msn.comCompare with Revolution Medicines Inc (RVMD)May 29 at 5:23 AM | marketbeat.comDimensional Fund Advisors LP Buys 133,558 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Dimensional Fund Advisors LP lifted its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,795,421 shares of the company's stock after buying an additional 133,558 shaMay 23, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 276,298 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Charles Schwab Investment Management Inc. increased its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 36.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,042,967 shareMay 22, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Hits New 52-Week High at $40.63Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High at $40.63May 22, 2024 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from BrokeragesMay 22, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Rating of "Buy" by BrokeragesRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has earned a consensus recommendation of "Buy" from the ten ratings firms that are covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coMay 17, 2024 | marketbeat.comSwiss National Bank Buys 36,531 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Swiss National Bank lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 22.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 200,131 shares of the company's stock after buying an additional 36,531 shares durMay 14, 2024 | marketbeat.comAnalysts Issue Forecasts for Revolution Medicines, Inc.'s Q1 2025 Earnings (NASDAQ:RVMD)Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Revolution Medicines in a report issued on Monday, May 13th. HC Wainwright analyst R. Burns expects that the company will post earninMay 13, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $44.00 target price on shares of Revolution Medicines in a research note on Monday.May 11, 2024 | marketbeat.comVictory Capital Management Inc. Has $16.01 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Victory Capital Management Inc. grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 63.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 558,369 shares of the company's stMay 10, 2024 | finance.yahoo.comRevolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...May 10, 2024 | finance.yahoo.comRevolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)May 9, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings ResultsRevolution Medicines (NASDAQ:RVMD - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. The company's revenue was down 100.0% compared to the same quarter last year. During the same period last year, the business posted ($0.72) earnings per share.May 9, 2024 | marketbeat.comWedbush Boosts Revolution Medicines (NASDAQ:RVMD) Price Target to $46.00Wedbush increased their price objective on shares of Revolution Medicines from $42.00 to $46.00 and gave the stock an "outperform" rating in a research report on Thursday.May 9, 2024 | finance.yahoo.comRevolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $46.00 price objective on shares of Revolution Medicines in a report on Thursday.May 8, 2024 | msn.comRVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024May 8, 2024 | globenewswire.comRevolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressMay 6, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Down 4.2% on Insider SellingRevolution Medicines (NASDAQ:RVMD) Stock Price Down 4.2% Following Insider SellingMay 5, 2024 | insidertrades.comJack Anders Sells 10,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockMay 4, 2024 | finance.yahoo.comInsider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)May 3, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) CFO Sells $400,300.00 in StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total transaction of $400,300.00. Following the transaction, the chief financial officer now directly owns 101,959 shares in the company, valued at $4,081,418.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.May 2, 2024 | marketbeat.comRevolution Medicines (RVMD) to Release Earnings on WednesdayRevolution Medicines (NASDAQ:RVMD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Reaches New 1-Year High at $39.00Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year High at $39.00May 1, 2024 | globenewswire.comRevolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024April 29, 2024 | marketbeat.comHandelsbanken Fonder AB Acquires 25,975 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Handelsbanken Fonder AB raised its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 182.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,175 shares of the company's stock after purcApril 27, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Purchases 38,363 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)State of New Jersey Common Pension Fund D lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 51.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 113,390 shares of the companyApril 27, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by AnalystsRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has earned a consensus rating of "Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the cApril 20, 2024 | marketbeat.comSG Americas Securities LLC Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)SG Americas Securities LLC lowered its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 93.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,595 shares of the company's stock after selling 54,206 shares during the pApril 19, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.Mirae Asset Global Investments Co. Ltd. increased its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 45.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,405 shares of the compApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - RVMDApril 17, 2024 | msn.comRevolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65April 15, 2024 | investing.comRevolution Medicines executive sells over $619k in company stockApril 14, 2024 | investing.comRevolution Medicines director sells shares worth $79,735April 13, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of StockApril 12, 2024 | marketbeat.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 7,500 Shares of StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark A. Goldsmith sold 7,500 shares of Revolution Medicines stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $35.48, for a total value of $266,100.00. Following the completion of the transaction, the insider now owns 452,879 shares in the company, valued at $16,068,146.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.April 12, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Short Interest Down 26.8% in MarchRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 12,000,000 shares, a decline of 26.8% from the March 15th total of 16,400,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 8.9 days.April 12, 2024 | markets.businessinsider.comBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer TherapiesApril 12, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) PT Raised to $45.00 at OppenheimerOppenheimer upped their price target on Revolution Medicines from $43.00 to $45.00 and gave the company an "outperform" rating in a report on Friday.April 11, 2024 | uk.investing.comRevolution Medicines reports progress in RAS cancer therapyApril 11, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $37.62Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month High at $37.62April 10, 2024 | msn.comWhat's Going On With Revolution Medicines Stock?April 10, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Upgraded to "Strong-Buy" at Raymond JamesRaymond James upgraded shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the stock from $36.00 to $48.00 in a research note on Wednesday.April 10, 2024 | uk.investing.comRevolution Medicines reports breakthrough in RAS-mutant cancer treatmentApril 9, 2024 | globenewswire.comRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 8, 2024 | markets.businessinsider.comRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy RatingApril 8, 2024 | globenewswire.comRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 4, 2024 | globenewswire.comRevolution Medicines to Participate in Upcoming Investor ConferencesMarch 29, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of StockMarch 29, 2024 | marketbeat.comVanguard Group Inc. Has $266.94 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)Vanguard Group Inc. increased its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 3.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,643,591 shares of the company's sto Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. RVMD Media Mentions By Week RVMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼1.420.82▲Average Medical News Sentiment RVMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼44▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXEL News HALO News PCVX News KRYS News IBRX News CRSP News IMVT News MRTX News RGEN News SWTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 5/31/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThis unknown company solves the biggest issue with AIManward PressWho are Nvidia’s New Silent Partners?Weiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBill Gates is all about this tiny $2 stockTimothy SykesDems have chosen Biden replacement?Paradigm PressGet out of dollars—get into America’s new money insteadStansberry ResearchDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist My Default Watchlist Adding Revolution Medicines, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
